Publications by authors named "You-Cai Li"
Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
World J Gastroenterol
January 2018
Article Synopsis
- The study aimed to explore how glucose metabolism relates to glypican-3 (GPC3) expression in patients diagnosed with hepatocellular carcinoma (HCC).
- Researchers performed immunohistochemical analysis and whole-body PET/CT scans on 55 HCC patients to measure GPC3 and glucose transporter (GLUT1) levels, as well as tumor glucose uptake.
- Results showed that GPC3 was positively expressed in a majority of patients and had an inverse relationship with glucose uptake, while GLUT1 showed a positive correlation; further regression analysis indicated that only the tumor-to-non-tumor uptake ratio was significantly related to GPC3 expression.
[Combined use of thin-section CT and F-FDG PET/CT for characterization of solitary pulmonary nodules].
Nan Fang Yi Ke Da Xue Xue Bao
March 2017
Objective: To investigate whether fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) combined with thin-section CT improves the diagnostic performance for solitary pulmonary nodules (SPNs).
Methods: A total of 267 patients underwent examinations with 18F-FDG PET/CT and thin-section CT for evaluating the SPNs with undetermined nature, which was further confirmed by pathological examination or clinical follow-up. The performance of two diagnostic criteria based on findings in PET/CT alone (Criterion 1) and in PET/CT combined with thin-section CT (Criterion 2) were compared.
Article Synopsis
- The study evaluates the necessity of whole-body F-FDG PET/CT scans for M staging in newly diagnosed nasopharyngeal carcinoma (NPC) patients, as not all patients benefit from this procedure.
- Analyzing data from 264 patients, researchers identified that factors such as EBV positivity and certain staging levels (N and T) were significantly associated with an increased risk of distant metastasis.
- The findings suggest that only patients categorized as medium or high risk, specifically those with elevated EBV DNA levels and advanced T or N staging, require the F-FDG PET/CT scan for effective M staging.